Business Wire

VA-REGULA

23.4.2024 09:01:33 CEST | Business Wire | Press release

Share
Regula Pinpoints Top Three Business Challenges with Verification of International Customers

In addition to the clear risks, such as an increase in fraud, attracting new foreign customers presents less apparent challenges, including the absence of standardized documentation and language barriers. These are the results of a global survey conducted by Regula, a global developer of forensic devices and identity verification solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423489077/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Top problems businesses deal with when verifying foreign IDs, according to Regula’s survey (Graphic: Business Wire)

Key challenges for businesses

When it comes to identity verification for international customers, including a growing community of digital nomads, organizations from various industries participating in Regula’s survey tend to point out the following challenges:

  • The lack of unified document standards. 41% of decision-makers in all sectors report a significant challenge due to the lack of standardized identity documents. This inconsistency affects the efficiency and speed of IDV processes. For government services, the problem seems to be even worse, since 48% of the respondents in this sphere named this issue as the main challenge.
  • The increase in fraud. Identity-related fraud continues to be a major concern, affecting 40% of businesses overall. Higher impacts of fraud are observed in Banking and Financial Services (48% of respondents call it a key challenge) and Retail (44% of respondents).
  • Language barriers. Complexities due to language differences are reported by 36% of businesses. For the Healthcare and Insurance industries, this is an even greater concern, with 41% and 39% of respondents correspondingly naming it among the top three challenges.

Dealing with new identity documents and facing new risks, organizations strive to pursue a high level of identity verification (IDV) security and accuracy, with every third of them expressing the need for an increase in their IDV budget by up to 20%.

"As the world is starting to pilot the concept of digital IDs, it is possible that in the foreseeable future, we will achieve a certain level of identity document standardization. That means some of the current challenges in international ID verification will likely be mitigated,” says Henry Patishman, Executive Vice President of Identity Verification Solutions at Regula. “In the meantime, both businesses and IDV providers have to concentrate on tackling fraud and language barriers. From our experience, we see that there are two effective ways of dealing with these issues: enhancing the set of document and biometric checks, with a strong emphasis on data cross-checks to spot any possible inconsistencies that may indicate fraud, and growing your own document knowledge database to be able to read any document in any language correctly.”

Major concerns for customers

In their turn, digital nomads who settle in foreign countries for short or long periods of time also face challenges related to identity verification. Predominantly, their concerns revolve around the document validity period, which has an expiry date and proof of residency, such as rental agreements or utility bills. Each of these issues is a challenge for 19% of Regula’s survey respondents.

Apart from that, 18% of digital nomads have difficulties with ID verification because of their frequent travel and changing locations, which create inconsistencies in the information provided, and potentially lead to delays or rejection in identity proofing. Another 18% of respondents feel a lack of trust and credibility from institutions due to the unconventional nature of their lifestyle and work arrangements.

As for the language barrier, 70% of digital nomads say they have encountered language difficulties in understanding the instructions during the verification process. However, only 16% of nomads cite language barriers as a top frustration during the ID verification process. At the same time, twice as many digital nomads (36%) feel frustrated because of Internet connectivity issues: majorly relying on public Wi-Fi networks, they face an increased risk of cybersecurity threats and data breaches during the verification process.

The research has also shown that only 29% of nomads are very comfortable with providing sensitive identification documents online while being in a foreign country.

To learn more about the concerns and frustrations for both businesses and digital nomads, read the full report on the survey. To find out how to cope with various difficulties during the identity verification process, please visit Regula’s solutions page and learn about the advanced technologies for document and biometric checks.

*The research was initiated by Regula and conducted by Sapio Research in September 2023 using an online survey of digital nomads and Fraud Prevention decision makers across the Software/Tech, Financial and Banking Services, Technology, Telecoms, Travel and Hospitality sectors, and others. The respondent geography included the US, UK, Germany, Spain, UAE, and Mexico.

Resources:

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240423489077/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye